Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.30%
#2 Victoria VR Victoria VR +9.12%
#3 Movement Movement +8.40%
#4 COTI COTI +7.33%
#5 DMT-NAT DMT-NAT +6.93%
#6 Palladium Network Palladium Network +4.63%
#7 Prom Prom +4.55%
#8 Test Test +4.07%
#9 GRVT Token GRVT Token +3.80%
#10 Cryptopia Cryptopia +3.74%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Response Genetics, Inc Response Genetics, Inc

Response Genetics, Inc

RGDXQ
Classement en actions #42156
Response Genetics, Inc., a life sciences company founded in Los Angeles,... Response Genetics, Inc., a life sciences company founded in Los Angeles, California, in 1999 (originally Bio Type, Inc., before its rebranding in August 2000), focuses on creating, advancing, and commercializing pharmacogenomic tests. These diagnostic tools are crucial for informing cancer treatment decisions by assessing specific indicators within tumor tissue samples that predict a patient's response to therapy. The company provides an extensive array of testing services, primarily through its ResponseDX suite, covering various cancers such as non-small cell lung, colorectal, gastric, gastroesophageal, melanoma, thyroid, breast, and glioma, in addition to a Tissue of Origin test. Beyond these existing solutions, Response Genetics is committed to expanding its diagnostic offerings to encompass other tumor types, while also delivering both the technical execution and professional interpretation components of its testing services. Operating globally, with a significant presence in the United States and Europe, Response Genetics serves a wide range of clients including community oncologists, pathologists, medical practices, hospitals, and pharmaceutical enterprises, primarily through its internal sales force.
Prix de l'action
$0.0001
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$3.87K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Response Genetics, Inc (RGDXQ)

Catégorie

Healthcare
Bénéfices pour Response Genetics, Inc (RGDXQ)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Response Genetics, Inc, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Response Genetics, Inc de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
$7.61B -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
$4.76B -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
- -
CN
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
$1.42B -
US
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
$-252.70M -
US